Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1997 7
1998 8
1999 10
2000 20
2001 23
2002 32
2003 23
2004 52
2005 61
2006 82
2007 111
2008 162
2009 162
2010 205
2011 198
2012 199
2013 171
2014 206
2015 224
2016 202
2017 258
2018 249
2019 263
2020 279
2021 283
2022 292
2023 273
2024 278
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,819 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and Pharmacodynamics of Posaconazole.
Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Chen L, et al. Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y. Drugs. 2020. PMID: 32323222 Free PMC article. Review.
Posaconazole is typically used for preventing invasive yeast and mold infections such as invasive aspergillosis in high-risk immunocompromised patients. ...Both new formulations require a loading dose on day 1 to achieve high posaconazole concentrations more quickly …
Posaconazole is typically used for preventing invasive yeast and mold infections such as invasive aspergillosis in high-risk immunoco …
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Maertens JA, et al. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1. Lancet. 2021. PMID: 33549194 Clinical Trial.
Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. ...Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole gro …
Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voric …
Antifungal agents.
Chen SC, Sorrell TC. Chen SC, et al. Med J Aust. 2007 Oct 1;187(7):404-9. doi: 10.5694/j.1326-5377.2007.tb01313.x. Med J Aust. 2007. PMID: 17908006 Review.
Clinically important "newer" agents include members of the echinocandin class (eg, caspofungin) and second-generation triazoles (eg, voriconazole and posaconazole). Voriconazole and posaconazole have broad-spectrum activity against yeasts and moulds, including Asper …
Clinically important "newer" agents include members of the echinocandin class (eg, caspofungin) and second-generation triazoles (eg, voricon …
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Free article. Clinical Trial.
Proven or probable invasive fungal infections were reported in 7 patients (2%) in the posaconazole group and 25 patients (8%) in the fluconazole or itraconazole group (absolute reduction in the posaconazole group, -6%; 95% confidence interval, -9.7 to -2.5%; P<0. …
Proven or probable invasive fungal infections were reported in 7 patients (2%) in the posaconazole group and 25 patients (8%) in the …
Posaconazole.
Keating GM. Keating GM. Drugs. 2005;65(11):1553-67; discussion 1568-9. doi: 10.2165/00003495-200565110-00007. Drugs. 2005. PMID: 16033292 Review.
Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. Posaconazole 800 mg/day demonstrated clinically relevant activity against a range of fungi in patients with invasive fungal infections wh …
Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. P …
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Agarwal SK, et al. Clin Ther. 2017 Feb;39(2):359-367. doi: 10.1016/j.clinthera.2017.01.003. Epub 2017 Feb 1. Clin Ther. 2017. PMID: 28161120 Clinical Trial.
When adjusted for different doses and nonlinearity, posaconazole was estimated to increase venetoclax C(max) and AUC(0-24) by 7.1- and 8.8-fold, respectively. ...Posaconazole can be used for antifungal prophylaxis in patients with acute myeloid leukemia receiving ve …
When adjusted for different doses and nonlinearity, posaconazole was estimated to increase venetoclax C(max) and AUC(0-24) by 7.1- an …
Posaconazole.
Bhattacharya M, Rajeshwari K, Dhingra B. Bhattacharya M, et al. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281. J Postgrad Med. 2010. PMID: 20622401
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. ...With the rising incidence of invasive fungal infections due to the HIV pandemic and medical a …
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive funga …
Posaconazole-Induced Pseudohyperaldosteronism.
Kuriakose K, Nesbitt WJ, Greene M, Harris B. Kuriakose K, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02130-17. doi: 10.1128/AAC.02130-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530850 Free PMC article.
A woman in her late 60s with disseminated histoplasmosis was treated with posaconazole because first-line therapies were not tolerated. She subsequently presented with decompensated heart failure, hypertension, and hypokalemia. ...
A woman in her late 60s with disseminated histoplasmosis was treated with posaconazole because first-line therapies were not tolerate …
Posaconazole-induced podocyte phospholipidosis.
Gilani S, Nasr SH, Sethi S. Gilani S, et al. Kidney Int. 2022 Mar;101(3):654. doi: 10.1016/j.kint.2021.08.004. Kidney Int. 2022. PMID: 35190046 No abstract available.
Posaconazole in immunocompromised pediatric patients.
Vicenzi EB, Cesaro S. Vicenzi EB, et al. Expert Rev Anti Infect Ther. 2018 Jul;16(7):543-553. doi: 10.1080/14787210.2018.1490177. Epub 2018 Jul 3. Expert Rev Anti Infect Ther. 2018. PMID: 29912581 Review.
Posaconazole is a broad-spectrum triazole widely used to prevent and treat invasive mycoses in adults. ...Further pediatric studies are needed especially for the new formulations of posaconazole (vials and tablets)....
Posaconazole is a broad-spectrum triazole widely used to prevent and treat invasive mycoses in adults. ...Further pediatric studies a …
3,819 results